InMed (INM) 10% Owner Vivo Opportunity Buys 20,546 Shares

What Happened Vivo Opportunity, LLC — reported as a 10% owner related to the record-holding funds — acquired a total of 20,546 shares of InMed Pharmaceuticals (INM) across transactions on July 14–16, 2026. All purchases were at $1.55 per share, for an aggregate reported cost of approximately $31,846. These transactions are coded "P" (purchase), i.e., open-market or private purchases.

Key Details

• Transaction dates/prices: 7/14/2026 — 4,882 shares and 493 shares @ $1.55; 7/15/2026 — 13,761 shares and 1,389 shares @ $1.55; 7/16/2026 — 19 shares and 2 shares @ $1.55. All purchases at $1.55 each.
• Total shares acquired: 20,546; total value ≈ $31,846.30.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing timeliness: Form 4 filed 2026-07-16 for trades dated 7/14–7/16 — appears timely under Section 16 reporting (filed within required window).
• Footnotes: Filings note Vivo Opportunity, LLC (and related Vivo Opportunity Cayman, LLC) act as general partners of the record-holding funds and disclaim beneficial ownership except to the extent of their pecuniary interest.

Context This report reflects purchases by an institutional/affiliate 10% owner (not an executive). Purchases (code P) are straightforward acquisitions — for many investors, insider purchases can be viewed as a more informative signal than routine sales, but the filing simply reports the transactions and includes partner/beneficial-ownership disclaimers; it does not explain motives.